Search
Search results
Talk & support service
Our Retina UK Talk & support service (formerly Telephone Befriending Service) links people who may be feeling isolated or lonely with a trained volunteer for regular contact.
Meet our Trustee: Colin McArthur
Colin McArthur re-joined the board in 2024 after serving as a trustee between January 2008 and September 2019.
Thomas Pocklington Trust and Sight Loss Councils ‘Cut it back’ campaign
TPT and Sight Loss Councils: Cut it back campaign
Webinar: Getting active: sport and sight loss with British Blind Sport
The latest webinar from Retina UK.
Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
Meet our Trustee: Dr Samuel Godfrey
Sam joins Retina UK, bringing a blend of scientific expertise, strategic leadership, and communication experience gained from over a decade working at Cancer Research UK.
One-Year Survival of Transplanted Cells Marks Progress in Early Retinal Regeneration Studies
Researchers have recently presented promising clinical data at the International Society for Stem Cell Research demonstrating that transplanted human neural progenitor cells survived for at least one year in participants with Retinitis Pigmentosa (RP).
Atsena Therapeutics present positive clinical data for XLRS gene therapy program
Promising early clinical trial results suggest that ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), could offer a potential new treatment approach for this rate inherited retinal condition.
VG801 gene therapy shows early promise for Stargardt disease in phase 1/2 clinical trial
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.